Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NORM: Nodular Lymphocyte-Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase 2 Trial With Either Rituximab or Mosunetuzumab

Next Previous
X
Search
Trial Profile

NORM: Nodular Lymphocyte-Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase 2 Trial With Either Rituximab or Mosunetuzumab

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mosunetuzumab (Primary) ; Fludeoxyglucose F-18; Hyaluronidase; Rituximab
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Acronyms NORM

    • Most Recent Events

    • 08 Dec 2024 Trial design presented at 66th American Society of Hematology Annual Meeting and Exposition.
    • 14 Nov 2023 Planned End Date changed from 31 Mar 2026 to 31 Oct 2026.
    • 14 Nov 2023 Planned primary completion date changed from 31 Mar 2026 to 31 Oct 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top